Drugs / Dihematoporphyrin derivative
last change Sep 1998 re-read 2 minutes ago

Dihematoporphyrin derivative

also known as DHP
Developed for
corneal neovascularization
Investigated by
Eastern Virginia Medical School · Medical College of Hampton Roads

Trials 1 · a red edge is where a trial was stopped

1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT00004430 Sep 1994 → Sep 1998 corneal neovascularization Medical College of Hampton Roads Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Dihematoporphyrin derivative ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004430
Known as DHP “Demonstrate the safety and efficacy of dihematoporphyrin derivative (DHP) in laser photodynamic therapy (PDT) in patients with corneal neovascularization.” NCT00004430
Route Topical “Patients receive topical dihematoporphyrin derivative (DHP) every 3 hours on days -3 and -2.” NCT00004430